Four Biotechs Face Challenges Amid U.S. COVID-19 Vaccine Funding CutsFDAU.S. COVID-19 vaccine biotechs face funding cuts, regulatory changes, and operational challenges. Learn how Vaxart, Novavax, GeoVax, and CastleVax navigate this uncertain landscape impacting future pandemic preparedness.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
